Aberdeen Group plc lowered its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 7.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 169,183 shares of the medical instruments supplier's stock after selling 13,892 shares during the period. Aberdeen Group plc owned approximately 0.24% of Insulet worth $43,931,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in Insulet by 27,298.6% in the first quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock valued at $1,744,100,000 after acquiring an additional 661,717 shares during the period. Nuveen LLC acquired a new position in Insulet in the first quarter worth about $74,163,000. Vanguard Group Inc. grew its stake in shares of Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock valued at $2,276,553,000 after purchasing an additional 178,976 shares during the last quarter. Northern Trust Corp raised its holdings in Insulet by 20.5% in the fourth quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier's stock worth $192,881,000 after purchasing an additional 125,710 shares during the period. Finally, Federated Hermes Inc. grew its position in Insulet by 23.4% in the first quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier's stock valued at $166,198,000 after purchasing an additional 120,197 shares in the last quarter.
Insulet Price Performance
NASDAQ PODD traded up $4.19 during mid-day trading on Friday, hitting $332.04. The stock had a trading volume of 131,830 shares, compared to its average volume of 763,107. Insulet Corporation has a twelve month low of $180.31 and a twelve month high of $334.18. The stock has a market capitalization of $23.37 billion, a price-to-earnings ratio of 100.94, a PEG ratio of 2.79 and a beta of 1.35. The firm's 50 day moving average is $300.42 and its 200 day moving average is $285.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.
Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. During the same quarter in the previous year, the business earned $0.55 earnings per share. The firm's revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have issued reports on PODD. Raymond James Financial reissued an "outperform" rating and issued a $360.00 price objective (up previously from $328.00) on shares of Insulet in a report on Tuesday, May 27th. The Goldman Sachs Group assumed coverage on shares of Insulet in a report on Friday, May 30th. They set a "buy" rating and a $380.00 price objective for the company. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Wolfe Research raised shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price on the stock in a research note on Tuesday, May 13th. Finally, Sanford C. Bernstein restated an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Sixteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $332.71.
Get Our Latest Stock Analysis on Insulet
About Insulet
(
Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
See Also
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access